Tag - ALBO

Developments

Albireo initiates Phase 3 Alagille syndrome trial

Albireo Pharma (NASDAQ:ALBO) launched a Phase 3 trial evaluating odevixibat for the treatment of Alagille syndrome, a rare genetic disorder that affects multiple parts of the body. Most Alagille patients present with...

December 17, 2020

Developments

Albireo Pharma presents positive Phase 3 odevixibat data

Albireo Pharma (NASDAQ:ALBO) presented positive results from two Phase 3 trials of odevixibat at the American Association for the Study of Liver Diseases meeting. Odevixibat is an ileal bile acid transport inhibitor...

November 13, 2020

Developments

Albireo Pharma ends development of elobixibat for NASH/NAFLD

Albireo Pharma (NASDAQ:ALBO) reported topline results from its Phase 2 trial evaluating elobixibat for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). The trial...

August 18, 2020

Developments

Albireo Pharma enrolls first patient in Phase 3 biliary atresia trial

Albireo Pharma (NASDAQ:ALBO) enrolled the first patient in its Phase 3 BOLD clinical trial of odevixibat for the treatment of biliary atresia. Odevixibat is an inhibitor of the ileal bile acid transporter and is...

July 14, 2020

Developments

Albireo Pharma completes patient enrollment in Phase 2 NASH/NAFLD study

Albireo Pharma (NASDAQ:ALBO) completed patient enrollment in its Phase 2 trial of elobixibat for the treatment of nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD). The trial enrolled 47...

March 10, 2020

Developments

Albireo Pharma presents positive Phase 2 data for pediatric cholestasis candidate

Albireo Pharma (NASDAQ:ALBO) presented positive Phase 2 data for its drug candidate, A4250, at The International Liver Congress 2019. A4250 is being developed to treat rare pediatric cholestatic liver diseases, where...

April 16, 2019

Tag - ALBO

Albireo initiates Phase 3 Alagille syndrome trial

Albireo Pharma presents positive Phase 3 odevixibat data

Albireo Pharma ends development of elobixibat for NASH/NAFLD

Albireo Pharma enrolls first patient in Phase 3 biliary atresia trial

Albireo Pharma completes patient enrollment in Phase 2 NASH/NAFLD study

Albireo Pharma presents positive Phase 2 data for pediatric cholestasis candidate

General

More